Stopping a GLP-1: regain risk and what happens after you quit

Stopping a GLP-1 is one of the most consequential decisions in this whole category, and the evidence on what happens afterward is now substantial enough to be genuinely useful rather than anecdotal. It's the flip side of the weight-loss timeline most people focus on — here's what the trials actually show once treatment ends.

The headline trial evidence

The clearest data comes from the STEP-1 trial extension, which followed participants after they stopped semaglutide and placebo alongside lifestyle intervention. Those who discontinued semaglutide regained a substantial share of the weight they had lost, along with a reversal of some of the cardiometabolic improvements seen during treatment, over roughly the following year¹. A broader systematic review and meta-analysis of discontinuation across liraglutide, semaglutide, and tirzepatide confirmed this isn't specific to one molecule — regain after stopping a GLP-1 is a consistent, well-documented pattern across the class²⁴.

Why this happens — it's not a willpower story

The same physiology behind weight-loss plateaus explains regain: your body's appetite-regulating hormones and energy expenditure adapted to a lower weight partly because the drug was counteracting the biological pressure to regain. Remove that counteracting effect and the underlying pressure — the same pressure that makes obesity so resistant to diet-and-exercise-only approaches in the first place — reasserts itself. This is exactly why obesity medicine increasingly treats these drugs as chronic-disease management rather than a finite course, the same framing used for blood pressure or cholesterol medication.

Real-world discontinuation patterns

Trial data describes what happens under close medical supervision, but real-world claims data adds a more sobering wrinkle: an analysis of GLP-1 discontinuation and reinitiation patterns among US adults found notably high rates of stopping the medication within the first year, for reasons ranging from side effects to cost to insurance coverage lapses — not always a deliberate, planned decision³. That matters because unplanned discontinuation (running out of medication, losing coverage, a compounded provider's supply interruption) carries the same regain risk as a deliberate stop, without the benefit of a plan for managing it.

What regained weight looks like

Regained weight isn't necessarily a return to your exact starting body composition — some evidence suggests regain can disproportionately affect fat mass in ways that interact with whatever lean mass was lost during treatment, which is one more reason preserving muscle while you're on the medication is worth taking seriously regardless of how long you plan to stay on it.

If you're considering stopping

A few things are worth doing before you stop, whenever possible: talk to your prescriber about why you're stopping and whether a lower maintenance dose or a slower taper might be a middle path rather than an abrupt stop; have a realistic plan for the lifestyle side (nutrition, activity, sleep) independent of the medication, since those habits matter more once the drug's appetite effect is gone, not less; and go in with accurate expectations rather than assuming the weight loss is now 'locked in.' If cost or access is why you're stopping, it's worth exploring alternatives before defaulting to quitting entirely — see how much does semaglutide cost, how much does tirzepatide cost, and our insurance coverage guide for options you may not have checked. If you're stopping specifically to plan a pregnancy, that's its own well-documented consideration — see GLP-1s and fertility/pregnancy. This is trial-based information, not a recommendation to stop or continue — that decision belongs with your prescriber.